Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 455

1.

Longitudinal antiretroviral adherence among adolescents infected with human immunodeficiency virus.

Murphy DA, Belzer M, Durako SJ, Sarr M, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network..

Arch Pediatr Adolesc Med. 2005 Aug;159(8):764-70.

PMID:
16061785
2.

Barriers to HAART adherence among human immunodeficiency virus-infected adolescents.

Murphy DA, Sarr M, Durako SJ, Moscicki AB, Wilson CM, Muenz LR; Adolescent Medicine HIV/AIDS Research Network..

Arch Pediatr Adolesc Med. 2003 Mar;157(3):249-55.

PMID:
12622674
3.

A prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women.

Howard AA, Arnsten JH, Lo Y, Vlahov D, Rich JD, Schuman P, Stone VE, Smith DK, Schoenbaum EE; HER Study Group..

AIDS. 2002 Nov 8;16(16):2175-82.

PMID:
12409739
4.

Hospital-based directly observed therapy for HIV-infected children and adolescents to assess adherence to antiretroviral medications.

Glikman D, Walsh L, Valkenburg J, Mangat PD, Marcinak JF.

Pediatrics. 2007 May;119(5):e1142-8. Epub 2007 Apr 23.

PMID:
17452493
5.

Depression and clinical progression in HIV-infected drug users treated with highly active antiretroviral therapy.

Bouhnik AD, Préau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, Gastaut JA, Moatti JP, Spire B; MANIF 2000 Study Group..

Antivir Ther. 2005;10(1):53-61.

PMID:
15751763
6.

Predictors of adherence to antiretroviral medications in children and adolescents with HIV infection.

Williams PL, Storm D, Montepiedra G, Nichols S, Kammerer B, Sirois PA, Farley J, Malee K; PACTG 219C Team..

Pediatrics. 2006 Dec;118(6):e1745-57. Epub 2006 Nov 13.

PMID:
17101712
7.

Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.

Nachega JB, Hislop M, Dowdy DW, Chaisson RE, Regensberg L, Maartens G.

Ann Intern Med. 2007 Apr 17;146(8):564-73.

PMID:
17438315
8.

Virologic and immunologic outcomes after 24 weeks in HIV type 1-infected adolescents receiving highly active antiretroviral therapy.

Flynn PM, Rudy BJ, Douglas SD, Lathey J, Spector SA, Martinez J, Silio M, Belzer M, Friedman L, D'Angelo L, McNamara J, Hodge J, Hughes MD, Lindsey JC; Pediatric AIDS Clinical Trial Group 381 Study Team..

J Infect Dis. 2004 Jul 15;190(2):271-9. Epub 2004 Jun 18.

PMID:
15216461
9.

Immunologic function and virologic suppression among children with perinatally acquired HIV Infection on highly active antiretroviral therapy.

Rutstein RM, Gebo KA, Flynn PM, Fleishman JA, Sharp VL, Siberry GK, Spector SA.

Med Care. 2005 Sep;43(9 Suppl):III15-22.

PMID:
16116305
10.

Changes in adherence to highly active antiretroviral therapy medications in the Multicenter AIDS Cohort Study.

Kleeberger CA, Buechner J, Palella F, Detels R, Riddler S, Godfrey R, Jacobson LP.

AIDS. 2004 Mar 5;18(4):683-8.

PMID:
15090774
11.

Effects of depression and selective serotonin reuptake inhibitor use on adherence to highly active antiretroviral therapy and on clinical outcomes in HIV-infected patients.

Horberg MA, Silverberg MJ, Hurley LB, Towner WJ, Klein DB, Bersoff-Matcha S, Weinberg WG, Antoniskis D, Mogyoros M, Dodge WT, Dobrinich R, Quesenberry CP, Kovach DA.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):384-90.

PMID:
18091609
12.

Preliminary outcomes of a paediatric highly active antiretroviral therapy cohort from KwaZulu-Natal, South Africa.

Reddi A, Leeper SC, Grobler AC, Geddes R, France KH, Dorse GL, Vlok WJ, Mntambo M, Thomas M, Nixon K, Holst HL, Karim QA, Rollins NC, Coovadia HM, Giddy J.

BMC Pediatr. 2007 Mar 17;7:13.

13.

Assessment of adherence to antiretroviral therapy in perinatally HIV-infected children and youth using self-report measures and pill count.

Farley JJ, Montepiedra G, Storm D, Sirois PA, Malee K, Garvie P, Kammerer B, Naar-King S, Nichols S; PACTG P1042S Team..

J Dev Behav Pediatr. 2008 Oct;29(5):377-84. doi: 10.1097/DBP.0b013e3181856d22.

PMID:
18714204
14.
15.

Risk factors for opportunistic illnesses in children with human immunodeficiency virus in the era of highly active antiretroviral therapy.

Ylitalo N, Brogly S, Hughes MD, Nachman S, Dankner W, Van Dyke R, Seage GR 3rd; Pediatric AIDS Clincial Trials Group Protocol 219C Team..

Arch Pediatr Adolesc Med. 2006 Aug;160(8):778-87.

PMID:
16894075
16.

Impact of early versus late adherence to highly active antiretroviral therapy on immuno-virological response: a 3-year follow-up study.

Carrieri MP, Raffi F, Lewden C, Sobel A, Michelet C, Cailleton V, Chêne G, Leport C, Moatti JP, Spire B; APROCO study group..

Antivir Ther. 2003 Dec;8(6):585-94.

PMID:
14760892
17.

CD4+ cell count, viral load, and highly active antiretroviral therapy use are independent predictors of body composition alterations in HIV-infected adults: a longitudinal study.

McDermott AY, Terrin N, Wanke C, Skinner S, Tchetgen E, Shevitz AH.

Clin Infect Dis. 2005 Dec 1;41(11):1662-70. Epub 2005 Oct 19.

PMID:
16267741
18.

Adherence to prescribed antiretroviral therapy in human immunodeficiency virus-infected children in the PENTA 5 trial.

Gibb DM, Goodall RL, Giacomet V, McGee L, Compagnucci A, Lyall H; Paediatric European Network for Treatment of AIDS Steering Committee..

Pediatr Infect Dis J. 2003 Jan;22(1):56-62.

PMID:
12544410
19.

Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data.

Protopopescu C, Raffi F, Roux P, Reynes J, Dellamonica P, Spire B, Leport C, Carrieri MP; ANRS CO8 APROCO-COPILOTE Study Group..

J Antimicrob Chemother. 2009 Sep;64(3):599-606. doi: 10.1093/jac/dkp232. Epub 2009 Jul 14.

PMID:
19602563
20.

Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study.

Patel K, Hernán MA, Williams PL, Seeger JD, McIntosh K, Van Dyke RB, Seage GR 3rd; Pediatric AIDS Clinical Trials Group 219/219C Study Team..

Clin Infect Dis. 2008 Feb 15;46(4):507-15. doi: 10.1086/526524.

PMID:
18199042

Supplemental Content

Support Center